Inflammation induced loss of skeletal muscle

Bone

Volumn 80, Issue , 2015, Pages 131-142

  Londhe, Priya ^a   Guttridge, Denis C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Atrophy; Cytokines; Differentiation; Inflammation; Muscle; Skeletal

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; MYOGENIC FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; CYTOKINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INCLUSION BODY MYOSITIS; INFLAMMATION; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE REGENERATION; MYOSITIS; NONHUMAN; PATHOGENESIS; POLYMYOSITIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; IMMUNOLOGY; METABOLISM;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; MUSCLE, SKELETAL; MUSCULAR ATROPHY;

EID: 84943621319     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.03.015     Document Type: Review

References (246)

1. Kablar B., Rudnicki M.A. Skeletal muscle development in the mouse embryo. Histol Histopathol 2000, 15:649-656.
2. Nabeshima Y., Hanaoka K., Hayasaka M., Esumi E., Li S., Nonaka I., et al. Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature 1993, 364:532-535.
3. Hasty P., Bradley A., Morris J.H., Edmondson D.G., Venuti J.M., Olson E.N., et al. Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. Nature 1993, 364:501-506.
4. Parker M.H., Seale P., Rudnicki M.A. Looking back to the embryo: defining transcriptional networks in adult myogenesis. Nat Rev Genet 2003, 4:497-507.
5. von Maltzahn J., Chang N.C., Bentzinger C.F., Rudnicki M.A. Wnt signaling in myogenesis. Trends Cell Biol 2012, 22:602-609.
6. Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001, 3:1014-1019.
7. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001, 3:1009-1013.
8. Baker J., Liu J.P., Robertson E.J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993, 75:73-82.
9. Liu J.P., Baker J., Perkins A.S., Robertson E.J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75:59-72.
10. Barton-Davis E.R., Shoturma D.I., Musaro A., Rosenthal N., Sweeney H.L. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A 1998, 95:15603-15607.
11. Coleman M.E., DeMayo F., Yin K.C., Lee H.M., Geske R., Montgomery C., et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 1995, 270:12109-12116.
12. Chakravarthy M.V., Abraha T.W., Schwartz R.J., Fiorotto M.L., Booth F.W. Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3'-kinase/Akt signaling pathway. J Biol Chem 2000, 275:35942-35952.
13. Flanagan-Steet H., Hannon K., McAvoy M.J., Hullinger R., Olwin B.B. Loss of FGF receptor 1 signaling reduces skeletal muscle mass and disrupts myofiber organization in the developing limb. Dev Biol 2000, 218:21-37.
14. Haddad F., Roy R.R., Zhong H., Edgerton V.R., Baldwin K.M. Atrophy responses to muscle inactivity. II. Molecular markers of protein deficits. J Appl Physiol (1985) 2003, 95:791-802.
15. Lecker S.H., Jagoe R.T., Gilbert A., Gomes M., Baracos V., Bailey J., et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004, 18:39-51.
16. Jagoe R.T., Lecker S.H., Gomes M., Goldberg A.L. Patterns of gene expression in atrophying skeletal muscles: response to food deprivation. FASEB J 2002, 16:1697-1712.
17. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708.
18. Dehoux M.J., van Beneden R.P., Fernandez-Celemin L., Lause P.L., Thissen J.P. Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. FEBS Lett 2003, 544:214-217.
19. Gomes M.D., Lecker S.H., Jagoe R.T., Navon A., Goldberg A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 2001, 98:14440-14445.
20. Li H.H., Kedar V., Zhang C., McDonough H., Arya R., Wang D.Z., et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 2004, 114:1058-1071.
21. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
22. Lee S.W., Dai G., Hu Z., Wang X., Du J., Mitch W.E. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 2004, 15:1537-1545.
23. Guttridge D.C., Mayo M.W., Madrid L.V., Wang C.Y., Baldwin A.S. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000, 289:2363-2366.
24. Sambasivan R., Yao R., Kissenpfennig A., Van Wittenberghe L., Paldi A., Gayraud-Morel B., et al. Pax7-expressing satellite cells are indispensable for adult skeletal muscle regeneration. Development 2011, 138:3647-3656.
25. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 1961, 9:493-495.
26. Heredia J.E., Mukundan L., Chen F.M., Mueller A.A., Deo R.C., Locksley R.M., et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell 2013, 153:376-388.
27. Tidball J.G., Wehling-Henricks M. Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo. J Physiol 2007, 578:327-336.
28. Tonlorenzi R., Dellavalle A., Schnapp E., Cossu G., Sampaolesi M. Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues. Curr Protoc Stem Cell Biol 2007, 3:B:2B.1:2B.1.1-2B.1.29.
29. Sampaolesi M., Blot S., D'Antona G., Granger N., Tonlorenzi R., Innocenzi A., et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006, 444:574-579.
30. Sampaolesi M., Torrente Y., Innocenzi A., Tonlorenzi R., D'Antona G., Pellegrino M.A., et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003, 301:487-492.
31. Mitchell K.J., Pannerec A., Cadot B., Parlakian A., Besson V., Gomes E.R., et al. Identification and characterization of a non-satellite cell muscle resident progenitor during postnatal development. Nat Cell Biol 2010, 12:257-266.
32. Joe A.W., Yi L., Natarajan A., Le Grand F., So L., Wang J., et al. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol 2010, 12:153-163.
33. Uezumi A., Fukada S., Yamamoto N., Takeda S., Tsuchida K. Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat Cell Biol 2010, 12:143-152.
34. Grounds M.D., Garrett K.L., Lai M.C., Wright W.E., Beilharz M.W. Identification of skeletal muscle precursor cells in vivo by use of MyoD1 and myogenin probes. Cell Tissue Res 1992, 267:99-104.
35. Seale P., Sabourin L.A., Girgis-Gabardo A., Mansouri A., Gruss P., Rudnicki M.A. Pax7 is required for the specification of myogenic satellite cells. Cell 2000, 102:777-786.
36. Yablonka-Reuveni Z., Rivera A.J. Temporal expression of regulatory and structural muscle proteins during myogenesis of satellite cells on isolated adult rat fibers. Dev Biol 1994, 164:588-603.
37. Cornelison D.D., Wold B.J. Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev Biol 1997, 191:270-283.
38. Bach E.A., Aguet M., Schreiber R.D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997, 15:563-591.
39. Young H.A. Regulation of interferon-gamma gene expression. J Interferon Cytokine Res 1996, 16:563-568.
40. Frucht D.M., Fukao T., Bogdan C., Schindler H., O'Shea J.J., Koyasu S. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol 2001, 22:556-560.
41. Flaishon L., Hershkoviz R., Lantner F., Lider O., Alon R., Levo Y., et al. Autocrine secretion of interferon gamma negatively regulates homing of immature B cells. J Exp Med 2000, 192:1381-1388.
42. Fukao T., Matsuda S., Koyasu S. Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. J Immunol 2000, 164:64-71.
43. Munder M., Mallo M., Eichmann K., Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 1998, 187:2103-2108.
44. Huang S., Hendriks W., Althage A., Hemmi S., Bluethmann H., Kamijo R., et al. Immune response in mice that lack the interferon-gamma receptor. Science 1993, 259:1742-1745.
45. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004, 75:163-189.
46. Gajewski T.F., Fitch F.W. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988, 140:4245-4252.
47. Decker T., Stockinger S., Karaghiosoff M., Muller M., Kovarik P. IFNs and STATs in innate immunity to microorganisms. J Clin Invest 2002, 109:1271-1277.
48. Bazan J.F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A 1990, 87:6934-6938.
49. O'Shea J.J., Gadina M., Schreiber R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002, 109:S121-S131. [Suppl.].
50. Morris A.C., Beresford G.W., Mooney M.R., Boss J.M. Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation. Mol Cell Biol 2002, 22:4781-4791.
51. Sun L., Ma K., Wang H., Xiao F., Gao Y., Zhang W., et al. JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts. J Cell Biol 2007, 179:129-138.
52. Cheng M., Nguyen M.H., Fantuzzi G., Koh T.J. Endogenous interferon-gamma is required for efficient skeletal muscle regeneration. Am J Physiol Cell Physiol 2008, 294:C1183-C1191.
53. Foster W., Li Y., Usas A., Somogyi G., Huard J. Gamma interferon as an antifibrosis agent in skeletal muscle. J Orthop Res 2003, 21:798-804.
54. Gasque P., Morgan B.P., Legoedec J., Chan P., Fontaine M. Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing. J Immunol 1996, 156:3402-3411.
55. Legoedec J., Gasque P., Jeanne J.F., Scotte M., Fontaine M. Complement classical pathway expression by human skeletal myoblasts in vitro. Mol Immunol 1997, 34:735-741.
56. Mantegazza R., Hughes S.M., Mitchell D., Travis M., Blau H.M., Steinman L. Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma. Neurology 1991, 41:1128-1132.
57. Reyes-Reyna S.M., Krolick K.A. Chemokine production by rat myocytes exposed to interferon-gamma. Clin Immunol 2000, 94:105-113.
58. Chen S.E., Jin B., Li Y.P. TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol 2007, 292:C1660-C1671.
59. Lagrota-Candido J., Vasconcellos R., Cavalcanti M., Bozza M., Savino W., Quirico-Santos T. Resolution of skeletal muscle inflammation in mdx dystrophic mouse is accompanied by increased immunoglobulin and interferon-gamma production. Int J Exp Pathol 2002, 83:121-132.
60. Rosen G.D., Sanes J.R., LaChance R., Cunningham J.M., Roman J., Dean D.C. Roles for the integrin VLA-4 and its counter receptor VCAM-1 in myogenesis. Cell 1992, 69:1107-1119.
61. Londhe P., Davie J.K. Gamma interferon modulates myogenesis through the major histocompatibility complex class II transactivator, CIITA. Mol Cell Biol 2011, 31:2854-2866.
62. Villalta S.A., Deng B., Rinaldi C., Wehling-Henricks M., Tidball J.G. IFN-gamma promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation. J Immunol 2011, 187:5419-5428.
63. Kalovidouris A.E., Plotkin Z., Graesser D. Interferon-gamma inhibits proliferation, differentiation, and creatine kinase activity of cultured human muscle cells. II. A possible role in myositis. J Rheumatol 1993, 20:1718-1723.
64. Londhe P., Davie J.K. Interferon-gamma resets muscle cell fate by stimulating the sequential recruitment of JARID2 and PRC2 to promoters to repress myogenesis. Sci Signal 2013, 6:ra107.
65. Caretti G., Di Padova M., Micales B., Lyons G.E., Sartorelli V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 2004, 18:2627-2638.
66. Wang X., Zhang Y., Yang X.O., Nurieva R.I., Chang S.H., Ojeda S.S., et al. Transcription of Il17 and Il17f is controlled by conserved noncoding sequence 2. Immunity 2012, 36:23-31.
67. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
68. Infante-Duarte C., Horton H.F., Byrne M.C., Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000, 165:6107-6115.
69. Ferretti S., Bonneau O., Dubois G.R., Jones C.E., Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003, 170:2106-2112.
70. Ramirez-Carrozzi V., Sambandam A., Luis E., Lin Z., Jeet S., Lesch J., et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 2011, 12:1159-1166.
71. Song X., Zhu S., Shi P., Liu Y., Shi Y., Levin S.D., et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol 2011, 12:1151-1158.
72. Iwakura Y., Ishigame H., Saijo S., Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011, 34:149-162.
73. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
74. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998, 160:3513-3521.
75. Chabaud M., Fossiez F., Taupin J.L., Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998, 161:409-414.
76. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
77. De Pasquale L., D'Amico A., Verardo M., Petrini S., Bertini E., De Benedetti F. Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy. Neurology 2012, 78:1309-1314.
78. Kishimoto T. Interleukin-6: from basic science to medicine-40years in immunology. Annu Rev Immunol 2005, 23:1-21.
79. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011, 1813:878-888.
80. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20.
81. Scheller J., Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 2006, 195:173-183.
82. Chalaris A., Rabe B., Paliga K., Lange H., Laskay T., Fielding C.A., et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007, 110:1748-1755.
83. Rabe B., Chalaris A., May U., Waetzig G.H., Seegert D., Williams A.S., et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008, 111:1021-1028.
84. Chen Q., Fisher D.T., Clancy K.A., Gauguet J.M., Wang W.C., Unger E., et al. Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol 2006, 7:1299-1308.
85. Bartoccioni E., Michaelis D., Hohlfeld R. Constitutive and cytokine-induced production of interleukin-6 by human myoblasts. Immunol Lett 1994, 42:135-138.
86. Fassone L., Gaidano G., Ariatti C., Vivenza D., Capello D., Gloghini A., et al. The role of cytokines in the pathogenesis and management of AIDS-related lymphomas. Leuk Lymphoma 2000, 38:481-488.
87. Pedersen B.K., Febbraio M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008, 88:1379-1406.
88. Baeza-Raja B., Munoz-Canoves P. p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol Biol Cell 2004, 15:2013-2026.
89. Serrano A.L., Baeza-Raja B., Perdiguero E., Jardi M., Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab 2008, 7:33-44.
90. Tsujinaka T., Fujita J., Ebisui C., Yano M., Kominami E., Suzuki K., et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996, 97:244-249.
91. Kurek J.B., Nouri S., Kannourakis G., Murphy M., Austin L. Leukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscle. Muscle Nerve 1996, 19:1291-1301.
92. Ahmed T.A., Buzzelli M.D., Lang C.H., Capen J.B., Shumate M.L., Navaratnarajah M., et al. Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes. Am J Physiol Gastrointest Liver Physiol 2007, 292:G1793-G1803.
93. Choy E.H., Isenberg D.A., Garrood T., Farrow S., Ioannou Y., Bird H., et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002, 46:3143-3150.
94. Nishimoto N., Kanakura Y., Aozasa K., Johkoh T., Nakamura M., Nakano S., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005, 106:2627-2632.
95. Brown M.A., Hural J. Functions of IL-4 and control of its expression. Crit Rev Immunol 1997, 17:1-32.
96. Choi P., Reiser H. IL-4: role in disease and regulation of production. Clin Exp Immunol 1998, 113:317-319.
97. Lombard-Platet S., Meyer V., Ceredig R. Both IFN-gamma and IL-4 induce MHC class II expression at the surface of mouse pro-B cells. Dev Immunol 1997, 5:115-120.
98. Mijatovic T., Kruys V., Caput D., Defrance P., Huez G. Interleukin-4 and -13 inhibit tumor necrosis factor-alpha mRNA translational activation in lipopolysaccharide-induced mouse macrophages. J Biol Chem 1997, 272:14394-14398.
99. Manna S.K., Aggarwal B.B. Interleukin-4 down-regulates both forms of tumor necrosis factor receptor and receptor-mediated apoptosis, NF-kappaB, AP-1, and c-Jun N-terminal kinase. Comparison with interleukin-13. J Biol Chem 1998, 273:33333-33341.
100. Kelly-Welch A.E., Hanson E.M., Boothby M.R., Keegan A.D. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003, 300:1527-1528.
101. Kelly-Welch A., Hanson E.M., Keegan A.D. Interleukin-4 (IL-4) pathway. Sci STKE 2005, 2005:cm9.
102. Vanhaesebroeck B., Stephens L., Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 2012, 13:195-203.
103. Horsley V., Jansen K.M., Mills S.T., Pavlath G.K. IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 2003, 113:483-494.
104. Marino M., Scuderi F., Mazzarelli P., Mannella F., Provenzano C., Bartoccioni E. Constitutive and cytokine-induced expression of MHC and intercellular adhesion molecule-1 (ICAM-1) on human myoblasts. J Neuroimmunol 2001, 116:94-101.
105. Barks J.L., McQuillan J.J., Iademarco M.F. TNF-alpha and IL-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells. J Immunol 1997, 159:4532-4538.
106. Tidball J.G., Villalta S.A. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2010, 298:R1173-R1187.
107. Odegaard J.I., Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol 2011, 6:275-297.
108. Lundberg I., Brengman J.M., Engel A.G. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995, 63:9-16.
109. Lepidi H., Frances V., Figarella-Branger D., Bartoli C., Machado-Baeta A., Pellissier J.F. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998, 24:73-79.
110. Lundberg I., Ulfgren A.K., Nyberg P., Andersson U., Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:865-874.
111. Fiorentino D.F., Bond M.W., Mosmann T.R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989, 170:2081-2095.
112. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
113. Spencer S.D., Di Marco F., Hooley J., Pitts-Meek S., Bauer M., Ryan A.M., et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 1998, 187:571-578.
114. Liu Y., Wei S.H., Ho A.S., de Waal Malefyt R., Moore K.W. Expression cloning and characterization of a human IL-10 receptor. J Immunol 1994, 152:1821-1829.
115. Tan J.C., Indelicato S.R., Narula S.K., Zavodny P.J., Chou C.C. Characterization of interleukin-10 receptors on human and mouse cells. J Biol Chem 1993, 268:21053-21059.
116. Carson W.E., Lindemann M.J., Baiocchi R., Linett M., Tan J.C., Chou C.C., et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995, 85:3577-3585.
117. Weber-Nordt R.M., Meraz M.A., Schreiber R.D. Lipopolysaccharide-dependent induction of IL-10 receptor expression on murine fibroblasts. J Immunol 1994, 153:3734-3744.
118. Gibbs V.C., Pennica D. CRF2-4: isolation of cDNA clones encoding the human and mouse proteins. Gene 1997, 186:97-101.
119. O'Farrell A.M., Liu Y., Moore K.W., Mui A.L. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J 1998, 17:1006-1018.
120. Riley J.K., Takeda K., Akira S., Schreiber R.D. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem 1999, 274:16513-16521.
121. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991, 147:3815-3822.
122. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
123. Lang R., Rutschman R.L., Greaves D.R., Murray P.J. Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter. J Immunol 2002, 168:3402-3411.
124. Lang R., Patel D., Morris J.J., Rutschman R.L., Murray P.J. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 2002, 169:2253-2263.
125. Schaer D.J., Boretti F.S., Hongegger A., Poehler D., Linnscheid P., Staege H., et al. Molecular cloning and characterization of the mouse CD163 homologue, a highly glucocorticoid-inducible member of the scavenger receptor cysteine-rich family. Immunogenetics 2001, 53:170-177.
126. Sulahian T.H., Hogger P., Wahner A.E., Wardwell K., Goulding N.J., Sorg C., et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 2000, 12:1312-1321.
127. Alvarez B., Quinn L.S., Busquets S., Lopez-Soriano F.J., Argiles J.M. TNF-alpha modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Lett 2002, 175:181-185.
128. Strle K., McCusker R.H., Tran L., King A., Johnson R.W., Freund G.G., et al. Novel activity of an anti-inflammatory cytokine: IL-10 prevents TNFalpha-induced resistance to IGF-I in myoblasts. J Neuroimmunol 2007, 188:48-55.
129. Strle K., McCusker R.H., Johnson R.W., Zunich S.M., Dantzer R., Kelley K.W. Prototypical anti-inflammatory cytokine IL-10 prevents loss of IGF-I-induced myogenin protein expression caused by IL-1beta. Am J Physiol Endocrinol Metab 2008, 294:E709-E718.
130. Deng B., Wehling-Henricks M., Villalta S.A., Wang Y., Tidball J.G. IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration. J Immunol 2012, 189:3669-3680.
131. Villalta S.A., Rinaldi C., Deng B., Liu G., Fedor B., Tidball J.G. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum Mol Genet 2011, 20:790-805.
132. Guo X., Wang X.F. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 2009, 19:71-88.
133. Gordon K.J., Blobe G.C. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta 2008, 1782:197-228.
134. Barcellos-Hoff M.H. Latency and activation in the control of TGF-beta. J Mammary Gland Biol Neoplasia 1996, 1:353-363.
135. Derynck R., Zhang Y., Feng X.H. Smads: transcriptional activators of TGF-beta responses. Cell 1998, 95:737-740.
136. Moustakas A., Heldin C.H. Non-Smad TGF-beta signals. J Cell Sci 2005, 118:3573-3584.
137. Javelaud D., Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 2005, 24:5742-5750.
138. Attisano L., Silvestri C., Izzi L., Labbe E. The transcriptional role of Smads and FAST (FoxH1) in TGFbeta and activin signalling. Mol Cell Endocrinol 2001, 180:3-11.
139. Rebbapragada A., Benchabane H., Wrana J.L., Celeste A.J., Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 2003, 23:7230-7242.
140. Kollias H.D., Perry R.L., Miyake T., Aziz A., McDermott J.C. Smad7 promotes and enhances skeletal muscle differentiation. Mol Cell Biol 2006, 26:6248-6260.
141. Liu D., Black B.L., Derynck R. TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev 2001, 15:2950-2966.
142. Allen R.E., Boxhorn L.K. Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. J Cell Physiol 1989, 138:311-315.
143. Florini J.R., Roberts A.B., Ewton D.Z., Falen S.L., Flanders K.C., Sporn M.B. Transforming growth factor-beta. A very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by Buffalo rat liver cells. J Biol Chem 1986, 261:16509-16513.
144. Vaidya T.B., Rhodes S.J., Taparowsky E.J., Konieczny S.F. Fibroblast growth factor and transforming growth factor beta repress transcription of the myogenic regulatory gene MyoD1. Mol Cell Biol 1989, 9:3576-3579.
145. Brennan T.J., Edmondson D.G., Li L., Olson E.N. Transforming growth factor beta represses the actions of myogenin through a mechanism independent of DNA binding. Proc Natl Acad Sci U S A 1991, 88:3822-3826.
146. Sime P.J., Xing Z., Graham F.L., Csaky K.G., Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997, 100:768-776.
147. Sinha M., Jang Y.C., Oh J., Khong D., Wu E.Y., Manohar R., et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 2014, 344:649-652.
148. Mendias C.L., Marcin J.E., Calerdon D.R., Faulkner J.A. Contractile properties of EDL and soleus muscles of myostatin-deficient mice. J Appl Physiol (1985) 2006, 101:898-905.
149. Zimmers T.A., Davies M.V., Koniaris L.G., Haynes P., Esquela A.F., Tomkinson K.N., et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002, 296:1486-1488.
150. Bootcov M.R., Bauskin A.R., Valenzuela S.M., Moore A.G., Bansal M., He X.Y., et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997, 94:11514-11519.
151. Eggers K.M., Kempf T., Lind L., Sundstrom J., Wallentin L., Wollert K.C., et al. Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. Scand J Clin Lab Invest 2012, 72:45-51.
152. Brown D.A., Moore J., Johnen H., Smeets T.J., Bauskin A.R., Kuffner T., et al. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum 2007, 56:753-764.
153. Wollert K.C., Kempf T., Lagerqvist B., Lindahl B., Olofsson S., Allhoff T., et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation 2007, 116:1540-1548.
154. Kempf T., Horn-Wichmann R., Brabant G., Peter T., Allhoff T., Klein G., et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 2007, 53:284-291.
155. de Jager S.C., Bermudez B., Bot I., Koenen R.R., Bot M., Kavelaars A., et al. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J Exp Med 2011, 208:217-225.
156. Bonaterra G.A., Zugel S., Thogersen J., Walter S.A., Haberkorn U., Strelau J., et al. Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury. J Am Heart Assoc 2012, 1:e002550.
157. Breit S.N., Johnen H., Cook A.D., Tsai V.W., Mohammad M.G., Kuffner T., et al. The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 2011, 29:187-195.
158. Grivennikov S.I., Tumanov A.V., Liepinsh D.J., Kruglov A.A., Marakusha B.I., Shakhov A.N., et al. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity 2005, 22:93-104.
159. Bakkar N., Wang J., Ladner K.J., Wang H., Dahlman J.M., Carathers M., et al. IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Cell Biol 2008, 180:787-802.
160. Li Y.P. TNF-alpha is a mitogen in skeletal muscle. Am J Physiol Cell Physiol 2003, 285:C370-C376.
161. Palacios D., Mozzetta C., Consalvi S., Caretti G., Saccone V., Proserpio V., et al. TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 2010, 7:455-469.
162. Acharyya S., Sharma S.M., Cheng A.S., Ladner K.J., He W., Kline W., et al. TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in duchenne muscular dystrophy. PLoS One 2010, 5:e12479.
163. Farber M.O., Mannix E.T. Tissue wasting in patients with chronic obstructive pulmonary disease. Neurol Clin 2000, 18:245-262.
164. Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425.
165. Nakayama M., Ishidoh K., Kayagaki N., Kojima Y., Yamaguchi N., Nakano H., et al. Multiple pathways of TWEAK-induced cell death. J Immunol 2002, 168:734-743.
166. Kaplan M.J., Ray D., Mo R.R., Yung R.L., Richardson B.C. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol 2000, 164:2897-2904.
167. Meighan-Mantha R.L., Hsu D.K., Guo Y., Brown S.A., Feng S.L., Peifley K.A., et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999, 274:33166-33176.
168. Wiley S.R., Cassiano L., Lofton T., Davis-Smith T., Winkles J.A., Lindner V., et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001, 15:837-846.
169. Wiley S.R., Winkles J.A. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003, 14:241-249.
170. Dogra C., Changotra H., Wedhas N., Qin X., Wergedal J.E., Kumar A. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 2007, 21:1857-1869.
171. Dohi T., Burkly L.C. The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol 2012, 92:265-279.
172. Burkly L.C., Michaelson J.S., Hahm K., Jakubowski A., Zheng T.S. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007, 40:1-16.
173. Hartupee J., Liu C., Novotny M., Li X., Hamilton T. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007, 179:4135-4141.
174. Killian K.J., Leblanc P., Martin D.H., Summers E., Jones N.L., Campbell E.J. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 1992, 146:935-940.
175. Bernard S., LeBlanc P., Whittom F., Carrier G., Jobin J., Belleau R., et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158:629-634.
176. Gosker H.R., Langen R.C., Bracke K.R., Joos G.F., Brusselle G.G., Steele C., et al. Extrapulmonary manifestations of chronic obstructive pulmonary disease in a mouse model of chronic cigarette smoke exposure. Am J Respir Cell Mol Biol 2009, 40:710-716.
177. Remels A.H., Gosker H.R., Langen R.C., Schols A.M. The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol (1985) 2013, 114:1253-1262.
178. Vorrink S.N., Kort H.S., Troosters T., Lammers J.W. Level of daily physical activity in individuals with COPD compared with healthy controls. Respir Res 2011, 12:33.
179. Hoppeler H., Kleinert E., Schlegel C., Claassen H., Howald H., Kayar S.R., et al. Morphological adaptations of human skeletal muscle to chronic hypoxia. Int J Sports Med 1990, 11(Suppl. 1):S3-S9.
180. Mizuno M., Savard G.K., Areskog N.H., Lundby C., Saltin B. Skeletal muscle adaptations to prolonged exposure to extreme altitude: a role of physical activity?. High Alt Med Biol 2008, 9:311-317.
181. Morrison W.L., Gibson J.N., Scrimgeour C., Rennie M.J. Muscle wasting in emphysema. Clin Sci (Lond) 1988, 75:415-420.
182. Shah O.J., Anthony J.C., Kimball S.R., Jefferson L.S. 4E-BP1 and S6K1: translational integration sites for nutritional and hormonal information in muscle. Am J Physiol Endocrinol Metab 2000, 279:E715-E729.
183. Plant P.J., Brooks D., Faughnan M., Bayley T., Bain J., Singer L., et al. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2010, 42:461-471.
184. Kirkham P., Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 2006, 111:476-494.
185. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000, 343:1594-1602.
186. Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907-916.
187. Houssiau F.A. Cytokines in rheumatoid arthritis. Clin Rheumatol 1995, 14(Suppl. 2):10-13.
188. Shingu M., Nagai Y., Isayama T., Naono T., Nobunaga M., Nagai Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993, 94:145-149.
189. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991, 10:4025-4031.
190. Butler D.M., Maini R.N., Feldmann M., Brennan F.M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995, 6:225-230.
191. Morel J.C., Park C.C., Woods J.M., Koch A.E. A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem 2001, 276:37069-37075.
192. Morel J.C., Park C.C., Zhu K., Kumar P., Ruth J.H., Koch A.E. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chem 2002, 277:34679-34691.
193. Morel J.C., Park C.C., Kumar P., Koch A.E. Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation. Lab Invest 2001, 81:1371-1383.
194. Joosten L.A., Netea M.G., Kim S.H., Yoon D.Y., Oppers-Walgreen B., Radstake T.R., et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A 2006, 103:3298-3303.
195. Suzuki M., Hashizume M., Yoshida H., Mihara M. Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int 2010, 30:309-315.
196. Mihara M., Hashizume M., Yoshida H., Suzuki M., Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012, 122:143-159.
197. Suzuki M., Hashizume M., Yoshida H., Shiina M., Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. Cytokine 2010, 51:178-183.
198. Nakahara H., Song J., Sugimoto M., Hagihara K., Kishimoto T., Yoshizaki K., et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003, 48:1521-1529.
199. Alonzi T., Fattori E., Lazzaro D., Costa P., Probert L., Kollias G., et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998, 187:461-468.
200. Sasai M., Saeki Y., Ohshima S., Nishioka K., Mima T., Tanaka T., et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999, 42:1635-1643.
201. Ohshima S., Saeki Y., Mima T., Sasai M., Nishioka K., Nomura S., et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A 1998, 95:8222-8226.
202. Hirano T., Matsuda T., Turner M., Miyasaka N., Buchan G., Tang B., et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988, 18:1797-1801.
203. Walsmith J., Roubenoff R. Cachexia in rheumatoid arthritis. Int J Cardiol 2002, 85:89-99.
204. Dinarello C.A., Roubenoff R. George Clowes' classic paper and the search for "muscle proteolysis factor". Nutrition 1996, 12:67-68.
205. Roubenoff R., Freeman L.M., Smith D.E., Abad L.W., Dinarello C.A., Kehayias J.J. Adjuvant arthritis as a model of inflammatory cachexia. Arthritis Rheum 1997, 40:534-539.
206. Dayer J.M. Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis?. J Rheumatol Suppl 2002, 65:10-15.
207. Hotamisligil G.S., Murray D.L., Choy L.N., Spiegelman B.M. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 1994, 91:4854-4858.
208. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
209. Roubenoff R., Roubenoff R.A., Cannon J.G., Kehayias J.J., Zhuang H., Dawson-Hughes B., et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994, 93:2379-2386.
210. Lecker S.H., Solomon V., Mitch W.E., Goldberg A.L. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999, 129:227S-237S.
211. Nishimoto N., Yoshizaki K., Maeda K., Kuritani T., Deguchi H., Sato B., et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003, 30:1426-1435.
212. Maini R.N., Taylor P.C., Szechinski J., Pavelka K., Broll J., Balint G., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006, 54:2817-2829.
213. van de Putte L.B., Rau R., Breedveld F.C., Kalden J.R., Malaise M.G., van Riel P.L., et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12week, phase II study. Ann Rheum Dis 2003, 62:1168-1177.
214. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
215. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleischmann R.M., Bulpitt K.J., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999, 130:478-486.
216. Mohler K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993, 151:1548-1561.
217. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204.
218. Campion G.V., Lebsack M.E., Lookabaugh J., Gordon G., Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996, 39:1092-1101.
219. van der Meulen M.F., Bronner I.M., Hoogendijk J.E., Burger H., van Venrooij W.J., Voskuyl A.E., et al. Polymyositis: an overdiagnosed entity. Neurology 2003, 61:316-321.
220. Amato A.A., Griggs R.C. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 2003, 61:288-289.
221. Carpenter S., Karpati G., Heller I., Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978, 28:8-17.
222. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. V: identification and quantitation of T8+ cytotoxic and T8+ suppressor cells. Ann Neurol 1988, 23:493-499.
223. Wiendl H., Mitsdoerffer M., Schneider D., Melms A., Lochmuller H., Hohlfeld R., et al. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003, 126:1026-1035.
224. Murata K., Dalakas M.C. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999, 155:453-460.
225. Dalakas M.C. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2006, 2:219-227.
226. De Bleecker J.L., De Paepe B., Vanwalleghem I.E., Schroder J.M. Differential expression of chemokines in inflammatory myopathies. Neurology 2002, 58:1779-1785.
227. Dalakas M.C. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 2012, 11:203-206.
228. Reimann J., Schnell S., Schwartz S., Kappes-Horn K., Dodel R., Bacher M. Macrophage migration inhibitory factor in normal human skeletal muscle and inflammatory myopathies. J Neuropathol Exp Neurol 2010, 69:654-662.
229. Luo Y.B., Mastaglia F.L. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta 2015, 1852(4):622-632.
230. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
231. Robinson A.B., Reed A.M. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011, 7:664-675.
232. Greenberg S.A., Pinkus J.L., Pinkus G.S., Burleson T., Sanoudou D., Tawil R., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57:664-678.
233. Page G., Chevrel G., Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004, 50:199-208.
234. Tournadre A., Miossec P. Interleukin-17 in inflammatory myopathies. Curr Rheumatol Rep 2012, 14:252-256.
235. Pedersen B.K. The diseasome of physical inactivity-and the role of myokines in muscle-fat cross talk. J Physiol 2009, 587:5559-5568.
236. Fischer C.P., Berntsen A., Perstrup L.B., Eskildsen P., Pedersen B.K. Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scand J Med Sci Sports 2007, 17:580-587.
237. Pedersen B.K. Muscles and their myokines. J Exp Biol 2011, 214:337-346.
238. Steensberg A., van Hall G., Osada T., Sacchetti M., Saltin B., Klarlund Pedersen B. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 2000, 529(Pt 1):237-242.
239. Izumiya Y., Bina H.A., Ouchi N., Akasaki Y., Kharitonenkov A., Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett 2008, 582:3805-3810.
240. Hede M.S., Salimova E., Piszczek A., Perlas E., Winn N., Nastasi T., et al. E-peptides control bioavailability of IGF-1. PLoS One 2012, 7:e51152.
241. Vinciguerra M., Musaro A., Rosenthal N. Regulation of muscle atrophy in aging and disease. Adv Exp Med Biol 2010, 694:211-233.
242. Duan C., Ren H., Gao S. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: roles in skeletal muscle growth and differentiation. Gen Comp Endocrinol 2010, 167:344-351.
243. Carbo N., Lopez-Soriano J., Costelli P., Alvarez B., Busquets S., Baccino F.M., et al. Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim Biophys Acta 2001, 1526:17-24.
244. Barra N.G., Chew M.V., Holloway A.C., Ashkar A.A. Interleukin-15 treatment improves glucose homeostasis and insulin sensitivity in obese mice. Diabetes Obes Metab 2012, 14:190-193.
245. Ouchi N., Oshima Y., Ohashi K., Higuchi A., Ikegami C., Izumiya Y., et al. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 2008, 283:32802-32811.
246. Raschke S., Eckel J. Adipo-myokines: two sides of the same coin-mediators of inflammation and mediators of exercise. Mediators Inflamm 2013, 2013:320724.